(MRA)], use of SGLT-2 inhibitors may reduce risk of mortality for patients with HFrEF by 73% over 2 years.4 However, as we laud SGLT-2 inhibitors as a major therapeutic advance, history has taught us that strong efficacy and safety in clinical trials are unfortunately not enough to ...
Tan B.Y.Q., Yeo T., Lee C., Lin W., Sia C. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Anal...
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemi...
本文由“天纳”临床学术信息人工智能系统自动翻译 In this video, Javed Butler, MD, introduces the series on the use of SGLT2 inhibitors in heart failure. He discusses the epidemiology of heart failure and the effects of...
(本文由北京大学第三医院药剂科翟所迪教授及其团队选题并审校,环球医学资讯编辑完成。) 参考资料: Lancet. 2022 Sep 3;400(10354):757-767 SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials https://pubmed.ncbi.nlm.nih.gov/36041474/...
[5]SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, August 27, 2022 [6]Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J, 27 August 2022 ...
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multic...
9 Williams, D. M., Nawaz, A. & Evans, M. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials.Diabetes Ther12, 55-70, doi:10.1007/s13300-020-00951-6 (2021). ...
[15].Efficacy and Safety of Sodium-Glucose Co-transporter-2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. AHA 2024. 本材料由阿斯利康提供,旨在满足您的医学信息需求,仅供医疗卫生专业人士参考,不用于推广目的。
[1] Vaduganathan M, et al., (2022). SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, doi: 10.1016/S0140-6736(22)01429-5. [2] Tuttle KR, e...